. 2023 Jun 1:14:1094698.

doi: 10.3389/fphar.2023.1094698. eCollection 2023.

Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies

R L Bromley^{1

2}, M Bickle Graz³, M Bluett-Duncan¹, C Chambers⁴, P Damkier⁵, K Dietrich⁶, H Dolk⁷, K Grant⁸, S Mattson⁹, K J Meador¹⁰, H Nordeng^{11

12}, T F Oberlander¹³, A Ornoy¹⁴, A Revet^{15

16}, J Richardson¹⁷, J Rovet^{18

19}, L Schuler-Faccini²⁰, E Smearman²¹, V Simms²², C Vorhees²³, K Wide²⁴, A Wood²⁵, L Yates^{26

27}, E Ystrom^{28

29}, T A Supraja³⁰, J Adams³¹

Affiliations

¹ Division of Neuroscience, Faculty of Medicine, School of Biological Sciences, Biology and Health, University of Manchester, Manchester, United Kingdom.
² Royal Manchester Children's Hospital, Manchester Academic Sciences Park, Manchester, United Kingdom.
³ Neonatology, Department Woman-Mother-Child, Lausanne University Hospital, Lausanne, Switzerland.
⁴ Division of Environmental Science and Health, Department of Pediatrics, University of California San Diego School of Medicine, San Diego, CA, United States.
⁵ Department of Clinical Pharmacology, Odense University Hospital, Denmark and Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
⁶ Department of Environmental and Public Health Sciences, Division of Epidemiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
⁷ Maternal, Fetal and Infant Research Unit, Faculty of Life and Health Sciences, Ulster University, Coleraine, United Kingdom.
⁸ Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, WA, United States.
⁹ Center for Behavioral Teratology, San Diego State University, San Diego, CA, United States.
¹⁰ Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, United States.
¹¹ Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway.
¹² Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway.
¹³ Department Pediatrics and School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
¹⁴ Hebrew University Hadassah Medical School, Adelson School of Medicine, Ariel University, Jerusalem, Israel.
¹⁵ INSERM University of Toulouse 3, Toulouse, France.
¹⁶ Department of Child and Adolescent Psychiatry, Toulouse University Hospital, Toulouse, France.
¹⁷ UK Teratology Information Service, Newcastle, United Kingdom.
¹⁸ Department of Psychology, University of Toronto, Toronto, ON, Canada.
¹⁹ The Hospital for Sick Children, Toronto, ON, Canada.
²⁰ Genetics Department, Hospital de Clinicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil.
²¹ Department of Surgery, Emory University, Atlanta, GA, United States.
²² School of Psychology, Faculty of Life and Health Sciences, Ulster University, Coleraine, United Kingdom.
²³ Department of Pediatrics, Division of Neurology, University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
²⁴ Department of Pediatrics, CLINTEC, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
²⁵ Clinical Sciences, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
²⁶ Northern Genetics Service, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom.
²⁷ KRISP, University of KwaZulu-Natal, Durban, South Africa.
²⁸ Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway.
²⁹ PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway.
³⁰ National Institute of Mental Health and Neurosciences NIMHANS, Bangalore, Karnataka, India.
³¹ Department of Psychology, University of Massachusetts Boston, Boston, MA, United States.

PMID: 37332344
PMCID: PMC10270323
DOI: 10.3389/fphar.2023.1094698

Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies

R L Bromley et al. Front Pharmacol. 2023.

. 2023 Jun 1:14:1094698.

doi: 10.3389/fphar.2023.1094698. eCollection 2023.

Authors

Affiliations

¹ Division of Neuroscience, Faculty of Medicine, School of Biological Sciences, Biology and Health, University of Manchester, Manchester, United Kingdom.
² Royal Manchester Children's Hospital, Manchester Academic Sciences Park, Manchester, United Kingdom.
³ Neonatology, Department Woman-Mother-Child, Lausanne University Hospital, Lausanne, Switzerland.
⁴ Division of Environmental Science and Health, Department of Pediatrics, University of California San Diego School of Medicine, San Diego, CA, United States.
⁵ Department of Clinical Pharmacology, Odense University Hospital, Denmark and Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
⁶ Department of Environmental and Public Health Sciences, Division of Epidemiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
⁷ Maternal, Fetal and Infant Research Unit, Faculty of Life and Health Sciences, Ulster University, Coleraine, United Kingdom.
⁸ Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, WA, United States.
⁹ Center for Behavioral Teratology, San Diego State University, San Diego, CA, United States.
¹⁰ Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, United States.
¹¹ Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway.
¹² Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway.
¹³ Department Pediatrics and School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
¹⁴ Hebrew University Hadassah Medical School, Adelson School of Medicine, Ariel University, Jerusalem, Israel.
¹⁵ INSERM University of Toulouse 3, Toulouse, France.
¹⁶ Department of Child and Adolescent Psychiatry, Toulouse University Hospital, Toulouse, France.
¹⁷ UK Teratology Information Service, Newcastle, United Kingdom.
¹⁸ Department of Psychology, University of Toronto, Toronto, ON, Canada.
¹⁹ The Hospital for Sick Children, Toronto, ON, Canada.
²⁰ Genetics Department, Hospital de Clinicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil.
²¹ Department of Surgery, Emory University, Atlanta, GA, United States.
²² School of Psychology, Faculty of Life and Health Sciences, Ulster University, Coleraine, United Kingdom.
²³ Department of Pediatrics, Division of Neurology, University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
²⁴ Department of Pediatrics, CLINTEC, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
²⁵ Clinical Sciences, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
²⁶ Northern Genetics Service, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom.
²⁷ KRISP, University of KwaZulu-Natal, Durban, South Africa.
²⁸ Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway.
²⁹ PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway.
³⁰ National Institute of Mental Health and Neurosciences NIMHANS, Bangalore, Karnataka, India.
³¹ Department of Psychology, University of Massachusetts Boston, Boston, MA, United States.

PMID: 37332344
PMCID: PMC10270323
DOI: 10.3389/fphar.2023.1094698

Abstract

Background: Exposure in utero to certain medications can disrupt processes of fetal development, including brain development, leading to a continuum of neurodevelopmental difficulties. Recognizing the deficiency of neurodevelopmental investigations within pregnancy pharmacovigilance, an international Neurodevelopmental Expert Working Group was convened to achieve consensus regarding the core neurodevelopmental outcomes, optimization of methodological approaches and barriers to conducting pregnancy pharmacovigilance studies with neurodevelopmental outcomes. Methods: A modified Delphi study was undertaken based on stakeholder and expert input. Stakeholders (patient, pharmaceutical, academic and regulatory) were invited to define topics, pertaining to neurodevelopmental investigations in medication-exposed pregnancies. Experts were identified for their experience regarding neurodevelopmental outcomes following medicinal, substances of misuse or environmental exposures in utero. Two questionnaire rounds and a virtual discussion meeting were used to explore expert opinion on the topics identified by the stakeholders. Results: Twenty-five experts, from 13 countries and professionally diverse backgrounds took part in the development of 11 recommendations. The recommendations focus on the importance of neurodevelopment as a core feature of pregnancy pharmacovigilance, the timing of study initiation and a core set of distinct but interrelated neurodevelopmental skills or diagnoses which require investigation. Studies should start in infancy with an extended period of investigation into adolescence, with more frequent sampling during rapid periods of development. Additionally, recommendations are made regarding optimal approach to neurodevelopmental outcome measurement, comparator groups, exposure factors, a core set of confounding and mediating variables, attrition, reporting of results and the required improvements in funding for potential later emerging effects. Different study designs will be required depending on the specific neurodevelopmental outcome type under investigation and whether the medicine in question is newly approved or already in widespread use. Conclusion: An improved focus on neurodevelopmental outcomes is required within pregnancy pharmacovigilance. These expert recommendations should be met across a complementary set of studies which converge to form a comprehensive set of evidence regarding neurodevelopmental outcomes in pregnancy pharmacovigilance.

Keywords: in utero exposure; medicines; neurobehavior; neurodevelopment; pharmacovigilance; pregnancy; teratogens.

Copyright © 2023 Bromley, Bickle Graz, Bluett-Duncan, Chambers, Damkier, Dietrich, Dolk, Grant, Mattson, Meador, Nordeng, Oberlander, Ornoy, Revet, Richardson, Rovet, Schuler-Faccini, Smearman, Simms, Vorhees, Wide, Wood, Yates, Ystrom, Supraja and Adams.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

**FIGURE 1**
Professional background and expertise of the neurodevelopmental expert working group.

See this image and copyright information in PMC

Cited by

Exposure to medication for neurological disease in pregnancy - time to consider the long-term implications?
Liu C, Pace S, Bromley R, Dobson R. Liu C, et al. EClinicalMedicine. 2023 Aug 24;63:102157. doi: 10.1016/j.eclinm.2023.102157. eCollection 2023 Sep. EClinicalMedicine. 2023. PMID: 37662523 Free PMC article. Review.
Core Data Elements for Pregnancy Pharmacovigilance Studies Using Primary Source Data Collection Methods: Recommendations from the IMI ConcePTION Project.
Richardson JL, Moore A, Bromley RL, Stellfeld M, Geissbühler Y, Bluett-Duncan M, Winterfeld U, Favre G, Alexe A, Oliver AM, van Rijt-Weetink YRJ, Hodson KK, Rezaallah B, van Puijenbroek EP, Lewis DJ, Yates LM. Richardson JL, et al. Drug Saf. 2023 May;46(5):479-491. doi: 10.1007/s40264-023-01291-7. Epub 2023 Mar 28. Drug Saf. 2023. PMID: 36976447 Free PMC article. Review.
Delphi Method Consensus on Statistical Analysis and Reporting Recommendations for Single-Arm Pregnancy Medication Safety Studies Investigating Pregnancy, Birth and Neonatal Health Outcomes: A Contribution from IMI-ConcePTION.
Richardson JL, Moore A, Stellfeld M, Geissbühler Y, Winterfeld U, Favre G, Chambers C, Beck E, Onken M, Dathe K, Ceulemans M, Diav-Citrin O, Shechtman S, Oliver AM, Hodson KK, Shiller DD, Alexe A, van Puijenbroek EP, Lewis DJ, Yates LM. Richardson JL, et al. Drug Saf. 2025 Jun;48(6):643-654. doi: 10.1007/s40264-025-01521-0. Epub 2025 Feb 5. Drug Saf. 2025. PMID: 39907983

References

1. Adams J., Barone S., LaMantia A., Philen R., Rice D. C., Spear L., et al. (2000). Workshop to identify critical windows of exposure for children's health: Neurobehavioral work group summary. Environ. Health Perspect. 108 (3), 535–544. 10.1289/ehp.00108s3535 - DOI - PMC - PubMed
1. Adams J., Lammer E. J. (1993). Neurobehavioral teratology of isotretinoin. Reprod. Toxicol. 7 (2), 175–177. 10.1016/0890-6238(93)90273-a - DOI - PubMed
1. Adams J. (2010). The neurobehavioral teratology of retinoids: A 50-year history. Birth Defects Res. A Clin. Mol. Teratol. 88 (10), 895–905. 10.1002/bdra.20721 - DOI - PubMed
1. Akins R. B., Tolson H., Cole B. R. (2005). Stability of response characteristics of a Delphi panel: Application of bootstrap data expansion. BMC Med. Res. Methodol. 5, 37. 10.1186/1471-2288-5-37 - DOI - PMC - PubMed
1. Altman D. G., Royston P. (2006). The cost of dichotomising continuous variables. Bmj 332 (7549), 1080. 10.1136/bmj.332.7549.1080 - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies

Affiliations

Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Miscellaneous

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources

Miscellaneous